FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225516110> ?p ?o ?g. }

• W4225516110 endingPage "2320" @default.
• W4225516110 startingPage "2307" @default.
• W4225516110 abstract "Ewing 2008R3 was conducted in 12 countries and evaluated the effect of treosulfan and melphalan high-dose chemotherapy (TreoMel-HDT) followed by reinfusion of autologous hematopoietic stem cells on event-free survival (EFS) and overall survival in high-risk Ewing sarcoma (EWS).Phase III, open-label, prospective, multicenter, randomized controlled clinical trial. Eligible patients had disseminated EWS with metastases to bone and/or other sites, excluding patients with only pulmonary metastases. Patients received six cycles of vincristine, ifosfamide, doxorubicin, and etoposide induction and eight cycles of vincristine, actinomycin D, and cyclophosphamide consolidation therapy. Patients were randomly assigned to receive additional TreoMel-HDT or no further treatment (control). The random assignment was stratified by number of bone metastases (1, 2-5, and > 5). The one-sided adaptive-inverse-normal-4-stage-design was changed after the first interim analysis via Müller-Schäfer method.Between 2009 and 2018, 109 patients were randomly assigned, and 55 received TreoMel-HDT. With a median follow-up of 3.3 years, there was no significant difference in EFS between TreoMel-HDT and control in the adaptive design (hazard ratio [HR] 0.85; 95% CI, 0.55 to 1.32, intention-to-treat). Three-year EFS was 20.9% (95% CI, 11.5 to 37.9) in TreoMel-HDT and 19.2% (95% CI, 10.8 to 34.4) in control patients. The results were similar in the per-protocol collective. Males treated with TreoMel-HDT had better EFS compared with controls: median 1.0 years (95% CI, 0.8 to 2.2) versus 0.6 years (95% CI, 0.5 to 0.9); P = .035; HR 0.52 (0.28 to 0.97). Patients age < 14 years benefited from TreoMel-HDT with a 3-years EFS of 39.3% (95% CI, 20.4 to 75.8%) versus 9% (95% CI, 2.4 to 34); P = .016; HR 0.40 (0.19 to 0.87). These effects were similar in the per-protocol collective. This observation is supported by comparable results from the nonrandomized trial EE99R3.In patients with very high-risk EWS, additional TreoMel-HDT was of no benefit for the entire cohort of patients. TreoMel-HDT may be of benefit for children age < 14 years." @default.
• W4225516110 created "2022-05-05" @default.
• W4225516110 creator A5000823591 @default.
• W4225516110 creator A5001373279 @default.
• W4225516110 creator A5006518748 @default.
• W4225516110 creator A5006986555 @default.
• W4225516110 creator A5007385743 @default.
• W4225516110 creator A5010565935 @default.
• W4225516110 creator A5010615884 @default.
• W4225516110 creator A5010739675 @default.
• W4225516110 creator A5011521711 @default.
• W4225516110 creator A5011634690 @default.
• W4225516110 creator A5015224690 @default.
• W4225516110 creator A5015373525 @default.
• W4225516110 creator A5015379488 @default.
• W4225516110 creator A5019784391 @default.
• W4225516110 creator A5021490889 @default.
• W4225516110 creator A5021915690 @default.
• W4225516110 creator A5025935523 @default.
• W4225516110 creator A5027623163 @default.
• W4225516110 creator A5030620194 @default.
• W4225516110 creator A5031540987 @default.
• W4225516110 creator A5032323430 @default.
• W4225516110 creator A5034265780 @default.
• W4225516110 creator A5037827311 @default.
• W4225516110 creator A5041527330 @default.
• W4225516110 creator A5042964289 @default.
• W4225516110 creator A5045183692 @default.
• W4225516110 creator A5048170384 @default.
• W4225516110 creator A5048836012 @default.
• W4225516110 creator A5051920004 @default.
• W4225516110 creator A5054084457 @default.
• W4225516110 creator A5055346726 @default.
• W4225516110 creator A5055408774 @default.
• W4225516110 creator A5057281435 @default.
• W4225516110 creator A5057288000 @default.
• W4225516110 creator A5057583620 @default.
• W4225516110 creator A5064672264 @default.
• W4225516110 creator A5080701980 @default.
• W4225516110 creator A5083161940 @default.
• W4225516110 creator A5083545252 @default.
• W4225516110 creator A5084241424 @default.
• W4225516110 creator A5088231310 @default.
• W4225516110 creator A5090206205 @default.
• W4225516110 date "2022-07-20" @default.
• W4225516110 modified "2023-10-18" @default.
• W4225516110 title "High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma" @default.
• W4225516110 cites W1592041923 @default.
• W4225516110 cites W1896775015 @default.
• W4225516110 cites W1963882854 @default.
• W4225516110 cites W1977467304 @default.
• W4225516110 cites W2038981426 @default.
• W4225516110 cites W2039316040 @default.
• W4225516110 cites W2041055738 @default.
• W4225516110 cites W2042936828 @default.
• W4225516110 cites W2044313879 @default.
• W4225516110 cites W2046131550 @default.
• W4225516110 cites W2048935051 @default.
• W4225516110 cites W2059707463 @default.
• W4225516110 cites W2069607843 @default.
• W4225516110 cites W2075302847 @default.
• W4225516110 cites W2115988398 @default.
• W4225516110 cites W2135594773 @default.
• W4225516110 cites W2159876545 @default.
• W4225516110 cites W2169323283 @default.
• W4225516110 cites W2213019416 @default.
• W4225516110 cites W2411092141 @default.
• W4225516110 cites W2743351613 @default.
• W4225516110 cites W2774451814 @default.
• W4225516110 cites W2977223621 @default.
• W4225516110 cites W2979469227 @default.
• W4225516110 cites W3006180429 @default.
• W4225516110 cites W3147894994 @default.
• W4225516110 cites W3152750978 @default.
• W4225516110 cites W3155165625 @default.
• W4225516110 cites W3165287952 @default.
• W4225516110 cites W3170933646 @default.
• W4225516110 cites W4211227438 @default.
• W4225516110 cites W4293241248 @default.
• W4225516110 doi "https://doi.org/10.1200/jco.21.01942" @default.
• W4225516110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35427190" @default.
• W4225516110 hasPublicationYear "2022" @default.
• W4225516110 type Work @default.
• W4225516110 citedByCount "20" @default.
• W4225516110 countsByYear W42255161102022 @default.
• W4225516110 countsByYear W42255161102023 @default.
• W4225516110 crossrefType "journal-article" @default.
• W4225516110 hasAuthorship W4225516110A5000823591 @default.
• W4225516110 hasAuthorship W4225516110A5001373279 @default.
• W4225516110 hasAuthorship W4225516110A5006518748 @default.
• W4225516110 hasAuthorship W4225516110A5006986555 @default.
• W4225516110 hasAuthorship W4225516110A5007385743 @default.
• W4225516110 hasAuthorship W4225516110A5010565935 @default.
• W4225516110 hasAuthorship W4225516110A5010615884 @default.
• W4225516110 hasAuthorship W4225516110A5010739675 @default.
• W4225516110 hasAuthorship W4225516110A5011521711 @default.
• W4225516110 hasAuthorship W4225516110A5011634690 @default.
• W4225516110 hasAuthorship W4225516110A5015224690 @default.

• next